entertainment -WSS

entertainment

author：explore 2025-09-30 20:47:24 - browse：23477

An AstraZeneca sign at ESMO in Madrid. — An AstraZeneca ad at ESMO 2023 in Madrid. Andrew Joseph/STAT

MADRID — Questions about one of AstraZeneca’s key cancer drug candidates — and the dribs and drabs that have come out about its performance — have been dogging the company for months.

On Monday, data presented here from a trial of the drug in advanced non-small cell lung cancer provided at least a fuller look. While the results assuaged some of the safety fears that flared when initial information was released over the summer, they only heightened concerns about the drug’s ability to outperform standard chemotherapy — though they perhaps pointed to an opportunity for the drug in a subset of patients.

The trial, detailed here in a prime session at the annual meeting of the European Society for Medical Oncology, is testing a therapy called datopotamab deruxtecan, or Dato-DXd, in advanced or metastatic non-small cell lung cancer in patients who already tried at least first-line treatments. Patients were randomized to either receive chemotherapy or Dato-DXd, which AstraZeneca is developing with Daiichi Sankyo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Travel bans should be based on evidence, not politics or fear

hotspot

knowledge

WSS

Readout LOUD podcast: brain research, obesity drug sales, Novartis

Zapping the brain for stroke rehab: Pivotal clinical trial begins

After gene therapy, two congenitally deaf children hear for the first time

Steward Health Care files for bankruptcy

Study: AI not yet building 'n

‘The Bear’ and hospitality in hospitals

focus

entertainment

explore

Jerome Adams on the need for new antivirals for Covid

An Ebola outbreak presents a new mystery involving children

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Elevance, private equity launch primary care company

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Trump attorney outlines possible Jan. 6 legal defenses, but some experts are skeptical

Trump demands the U.S. pay no more for drugs than other countries … again

A year after a Russian missile took her leg, a young Ukrainian gymnast's spirit endures

The cancer drug shortage isn’t new — and neither are the solutions

Ohioans vote in high

explore

In venture capital firm's success, lessons for turning crisis into profit

NYC struggling to keep up with demand of supporting asylum seekers, Mayor Adams says

'Of course' Trump lost the 2020 election, DeSantis says after years of hedging

Sage's campaign to raise awareness of postpartum depression hits a nerve

Cheesesteak restaurant owner explains his secret sauce, the viral Malibu Barbie Dream Drizzle

H5N1 bird flu: what we're starting to learn about infection in cows

hotspot

knowledge

hotspot

leisure time